De Novo Pharmaceuticals
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
9th April 2007
CAMBRIDGE, England and SANTA ROSA, California - De Novo Pharmaceuticals Ltd, a world leader in computational drug design, has announced that it has completed work on the in silico design of novel inhibitors for 11 beta-hydroxysteroid dehydrogenase. This work is available for partnering opportunities.

De Novo is applying SkelGen®, the Company’s proprietary in silico drug design platform, to the design of new compounds for significant targets within the diabetes field. SkelGen is a structure-based drug design technology platform that has been shown to improve the speed and effectiveness of the drug discovery process.

Philip Dean, Chief Scientific Officer at De Novo, commented: "Metabolic disease is an important therapeutic area with many targets that present a major opportunity for De Novo`s technologies. The design of many novel scaffolds for this key diabetes target extends the Company`s capabilities and is our first program in this new therapeutic area."

Print this page

Recent News
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform